The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

16 Dec 2008 07:00

RNS Number : 1787K
ViaLogy PLC
16 December 2008
 



ViaLogy PLC ("ViaLogy" or "the Company")

ViaLogy reports 'significant technical progress' in Interim Report

December 16th 2008. ViaLogy PLC today issued its Interim Report for the six-month period to September 30, 2008. The Company showed a loss for the period of £2,597,102, which included £1,176,605 for amortisation and depreciation. The amortisation charge relates to the value of ViaLogy's Intellectual Property and associated Research and Development, which is amortised over a total of six years. The cash outflow from operations during the six months was £1,348,898.

In a trading update accompanying the report ViaLogy's Chief Executive, Robert W. Dean, said that considerable progress is being made in the two sectors where it is focussing its principal commercial efforts, Safety and Security, and Oil and Gas. Working closely with San Antonio-based partner Atascosa Exploration LLP, ViaLogy has determined the location of an additional hydrocarbon gas reservoir. Using QuantumRD, ViaLogy's proprietary technology for geoseismic analysis that assesses the location, capacity and payout of hydrocarbon reservoirs, Atascosa plans to complete drilling in January 2009. ViaLogy is also fixing the location of another oil reservoir for Atascosa, and determining the optimal drill location. Drilling on this second project should also be completed in the January/February 2009 timeframe.

"Success with these projects will give ViaLogy a 5% working interest in their output, and should mark a major milestone in proof-of-concept acceptance of the QuantumRD technology by the oil and gas exploration industry," said Mr. Dean. "ViaLogy intends to market its QuantumRD product aggressively, and to enter immediately into additional drilling projects with Atascosa."

Mr. Dean also confirmed significant progress in productizing ViaLogy's core Intellectual Property, Quantum Resonance Interferometry (QRI™), with its application to precisely geolocate buried oil and gas pipeline. This application of QRI™ is branded as QSUB™. QRI™ itself is a tool for the extraction of hard-to-find information from sensor data that frustrate other software processing techniques; it has wide applicability in that it can be applied to data from virtually any type of sensor. Precisely locating buried pipeline more cost effectively than current techniques is a business service for which ViaLogy believes there is a substantial market, and for which ViaLogy believes QSUB™ has a direct and cost-cutting application. ViaLogy's work over the last six months has been to demonstrate a new approach that is dependable, robust, and meets pipeline industry criteria. 

"We have not encountered any setback with the application of the QRI™ technology," said Mr. Dean. "Working within ViaLogy's resource constraints, and using multiple synthetic aperture radar data sets to confront the technology with a demanding variety of soil conditions, ViaLogy is showing that QSUB™  can both locate otherwise impossible-to-find buried metal objects, and improve radar's performance by determining when it produces false alarms. This work translates directly into the pipeline application. We hope to be able to report major milestones in the first quarter of 2009 about carrying the pipeline business forward."

In the Physical Security Information Management market, ViaLogy's flagship security software product SPM™ (Sensor Policy Manager™) has made major steps forward in the face of economic and business challenges in the security software business stemming from difficulties in the wider economy. "Our Canadian partner Axia Supernet has decided to expand a joint SPM™ air quality monitoring operational pilot as a step toward winning customer acceptance of a province-wide deployment. SPM™ is operating in Los Angeles County as the core piece of a chemical toxin early warning system sponsored by the US Department of Health & Safety and the Company expects this system to be expanded in LA County and further deployed to other major US cities. In cooperation with a major US defense contractor, ViaLogy has successfully integrated multiple perimeter surveillance radars into an Air Force Asian base security system and ViaLogy expects further orders for other bases; SPM™ is also being evaluated for supporting US Army base security systems. In addition, one of  ViaLogy's partners, Cisco Systems Inc, has put in place a targeted marketing effort for its COPSS integrated security solution; SPM™ is an integral part of COPSS and Cisco Systems Inc and ViaLogy are jointly approaching major potential customers. In summary, the Company has a growing sales pipeline for its SPM™ and looks toward substantial income in 2009.

Commenting on the Interim Report, ViaLogy's chairman, Terry Bond, said the board was pleased with the continuing progress being made by the company. In August 2008 ViaLogy raised £1.8 million by way of a placing of 45 million new ordinary shares at 4p per share. In addition, subject to shareholder approval which was subsequently given at the AGM, the placees received one warrant for every ordinary share purchased in the placing. Each warrant entitles the holder to purchase an additional ordinary share at 5p at any time up to 29 October 2011.

"Our work throughout 2008 has been carried out in an international financial and commercial environment that is the most difficult I have ever experienced," said Mr. Bond. "In such circumstances it is incumbent upon small companies such as ViaLogy, with a strong technology potential but yet to make its commercial mark, to be prudent in its financial planning. We have looked carefully at every aspect of our overhead expenditure and made cost savings wherever possible. In addition, directors and staff have agreed to make personal financial sacrifices to ensure the continued well-being of the Company and I thank them on behalf of the board and the shareholders."

For further information please contact:

ViaLogy

Robert W. Dean, President and CEO - US. +1 626-296-6337

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734

Nominated Adviser (Seymour Pierce)

Mark Percy +44 (0) 207-107-8000

Brokers

St. Helens Capital +44 (0) 207-628-5582

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTGUGCAPUPRGQA
Date   Source Headline
15th May 20187:00 amRNSYear-end Trading Update and £2.5m Fundraising
30th Apr 20184:00 pmRNSNotice of Trading Update
29th Mar 20187:00 amRNSPremaitha to attend industry conferences in APAC
26th Mar 20187:00 amRNSUpdate on UK patent infringement claim
16th Feb 20187:00 amRNSPremaitha secures market entry into Egypt
14th Feb 201810:25 amRNSHolding(s) in Company
12th Feb 20187:00 amRNSThermo Fisher - issue of warrants
6th Feb 20187:00 amRNSPremaitha to attend key conferences in Middle East
5th Feb 20187:00 amRNSPremaitha's IONA test approved for sale in Brazil
24th Jan 20187:00 amRNSUK High Court grants right to appeal
22nd Jan 20187:00 amRNSSecured loan facility agreement with Thermo Fisher
29th Dec 20177:00 amRNSHalf Year Results
11th Dec 20177:00 amRNSPremaitha secures four further laboratories in EU
1st Dec 20179:40 amRNSPremaitha CEO Wins Outstanding Contribution Award
27th Nov 20177:00 amRNSMiddle East laboratory network expansion
23rd Nov 20177:00 amRNSPremaitha signs new partner in East Asia
21st Nov 201710:47 amRNSLitigation First Instance Judgment
30th Oct 201710:08 amRNSGrant of Share Options
24th Oct 20173:45 pmRNSResult of AGM
24th Oct 20177:00 amRNSAGM Statement
13th Oct 20177:00 amRNSMiddle East Update
29th Sep 20177:04 amRNSFinal Results
29th Sep 20177:01 amRNSNotice of AGM
21st Sep 20174:05 pmRNSHolding(s) in Company
19th Sep 20177:00 amRNSPremaitha to offer NIPT in South Africa
7th Sep 20173:10 pmRNSFurther Patent Infringement Claims
29th Aug 20177:00 amRNSApproved for Good Manufacturing Process in Brazil
18th Jul 20172:02 pmRNSHolding(s) in Company
12th Jul 20177:00 amRNSInvestment Agreement Extension with Thermo Fisher
10th Jul 20177:00 amRNSPremaitha announces two laboratory hub contracts
3rd Jul 20177:00 amRNSLitigation Update
27th Jun 20177:00 amRNSHolding(s) in Company
16th Jun 20177:00 amRNSPremaitha launches Sage NIPT solution
5th Jun 20177:00 amRNSIndia Business Update
26th May 20177:00 amRNSIONA test validation on Thermo Fisher's Ion S5
19th May 20172:30 pmRNSPremaitha welcomes NIPT recommendation in France
16th May 20177:00 amRNSYear End Trading Update
12th May 20172:15 pmRNSUpdate Re. Swiss Customer
3rd Apr 20174:48 pmRNSHolding(s) in Company
31st Mar 20174:00 pmRNSSecond tranche of warrants issued to Thermo Fisher
17th Mar 20177:15 amRNSHardman Research: Expanding global distribution
13th Mar 20177:00 amRNSPremaitha to Attend International Medical Events
2nd Mar 201711:03 amRNSCompletion of Yourgene Acquisition
27th Feb 20177:00 amRNSCompletion of Acquisition
22nd Feb 20179:37 amRNSHolding(s) in Company
20th Feb 20177:00 amRNSMiddle East Business Update
16th Feb 20175:34 pmRNSHolding(s) in Company
15th Feb 20177:00 amRNSIssue of Equity
14th Feb 20179:32 amRNSHolding(s) in Company
13th Feb 20177:00 amRNSNew partnership with European diagnostics group

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.